EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring

Fang Cheng, Fan Wang, Zheng Cui, Qiang Li, Xin Liu, Weiming Li

Drug Design, Development and Therapy · 2026-06 · Volume 20 · 1-10

DOI: 10.2147/dddt.s612207 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-06. Verfasst von Fang Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, Pe…. Hauptthemen laut MEDLINE: Aminopyridines, Antineoplastic Agents, Benzamides, Drug Monitoring. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesAntineoplastic AgentsBenzamidesDrug MonitoringLeukemia, Myeloid, Chronic-PhaseTyrosine Kinase InhibitorsAdultFemaleHumansMaleMiddle AgedChinaDose-Response Relationship, DrugEast Asian People

Stichwörter der Autor:innen

chromic myeloid leukemiaexposure-efficacyexposure-toxicityflumatinibtherapeutic drug monitoring

Substanzen

AminopyridinesAntineoplastic AgentsBenzamidesflumatinibTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, Hubei, People's Republic of China.
  • Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
  • Department of Hematology, Suizhou Hospital, Hubei University of Medicine, Suizhou, 441300, Hubei, People's Republic of China.
  • Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.

Zitieren

APA

Cheng, F., Wang, F., Cui, Z., Li, Q., Liu, X., & Li, W. (2026). Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring. Drug Design, Development and Therapy, Volume 20, 1-10. https://doi.org/10.2147/dddt.s612207

Vancouver

Cheng F, Wang F, Cui Z, Li Q, Liu X, Li W. Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring. Drug Design, Development and Therapy. 2026;Volume 20:1-10. doi:10.2147/dddt.s612207

BibTeX
@article{Cheng2026,
  author = {Cheng, Fang and Wang, Fan and Cui, Zheng and Li, Qiang and Liu, Xin and Li, Weiming},
  title = {Optimizing Flumatinib Therapy in Chinese Chronic-Phase Chronic Myeloid Leukemia Based on Therapeutic Drug Monitoring},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  volume = {Volume 20},
  pages = {1--10},
  doi = {10.2147/dddt.s612207}
}
Kostenlos starten →